Global Human Embryonic Stem Cell Laws and Policies and Their Influence on Stem Cell Tourism
By Nishakanthi Gopalan et al.,
Biotechnology Law Report
| 10. 09. 2018
Abstract
Stem cell (SC) technology has spurred many debates among experts which highlight both the deficiency of current regulation and the growing need for better oversight. The benefit of better regulating SC technology is easily understood by studying the variety of laws and policies available. Previous compilations, last published in 2009, are outdated, calling for an update. Therefore, this study aims to bring up to date the laws and policies relating to human embryonic stem cells (HESC) and to identify emerging trends in regulation. The review of numerous legal documents, including bills and legislation, accessed through official government portals, found that all developed countries have sound legislation promoting research. While some developed nations have gaps within their otherwise-sound regulation, a more pressing issue is growing travel for treatment (“SC tourism”) to developing and under-developed countries where SC technology is under- or unregulated. Therefore, SC tourism is no longer a country issue; rather, it is a universal dilemma requiring international effort for a resolution.
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...